Asian Annals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Josep M Gimferrer
Carlos A Mestres
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gimferrer, J. M
Right arrow Articles by Mestres, C. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gimferrer, J. M
Right arrow Articles by Mestres, C. A
Related Collections
Right arrow Lung - other
Asian Cardiovasc Thorac Ann 2005;13:201-202
© 2005 Asia Publishing EXchange Ltd


EDITORIAL

Role of Surgery in Drug-Resistant Pulmonary Tuberculosis

Josep M Gimferrer, MD, Carlos A Mestres, MD

Spain

The first 20% of the full text of this article appears below.

INTRODUCTION

The role of surgery in pulmonary tuberculosis (TB) has changed from collapse therapy. Before chemotherapy, pulmonary resection for TB had a prohibitive operative mortality rate of 20–40%. The efficacy of modern antimycobacterial chemotherapy drastically reduced the indications for pulmonary resection to the treatment of complications of TB or sequelae such as tracheal or bronchial stenosis, aspergillomas growing on cavitated lesions, bronchiectasis, destroyed lungs, massive hemoptysis, bronchopleural fistulas, empyema, and also to rule out lung cancer in patients with pulmonary masses. Currently, the prevalence of TB remains high in many areas of the world. Resistance to antituberculous drugs has been noticed since the drugs were first introduced. During the 1980s, the epidemic of AIDS, changes in immigration patterns throughout the world, intravenous drug abuse, delay in diagnosis, insufficient health care infrastructures, and inappropriate treatments led to an increased incidence of resistance to chemotherapy, thereby allowing the emergence of multidrug-resistant tuberculosis (MDR-TB) as the most frequent indication for surgery in patients with localized TB lesions and a sufficient expected cardiovascular function after resection.1

MULTIDRUG-RESISTANT TUBERCULOSIS

MDR-TB is caused by Mycobacterium tuberculosis strains that are resistant to at least rifampin and isoniazid. Mutations can produce bacilli resistant to any of the currently used drugs against TB. Drug resistance may be primary or secondary. Primary . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by the Asia Publishing EXchange Ltd.